medigraphic.com

2015, Number 1

<< Back Next >>

Rev Mex Anest 2015; 38 (1)

Prothrombin complex concentrate in the perioperative

Carrillo-Esper R, de los Monteros-Estrada IE, Rosales-Gutiérrez AO, Zepeda-Mendoza AD, Alonso-Martínez D, Sánchez-Moreno MA, Cabrera-Joachin CM

Language: Spanish
References: 35
Page: 35-43
PDF size: 240.66 Kb.


ABSTRACT

Prothrombin complex concentrates are a purified drug products with hemostatic activity derived from a plasma pool. Prothrombin complex concentrates contain a given and proportional amount of four non-activated vitamin-K dependent coagulation factors, a variable amount of anticoagulant proteins and low dose heparin. Prothrombin complex concentrates offers a means for the rapid reversal of warfarin, particulary in the setting of life-threatening bleeding. Prothrombin complex concentrates are recommended as an alternative to fresh frozen plasma and recombinant factor VIIa to the treatment of serious bleeding related to vitamin K antagonist. Studies in this setting have show that prothrombin complex concentrates are safe and effective and provide prompt reduction of international normalized ratio. Other indications include coagulopathy due to hepatic failure, traumatic hemorrhage and new oral anticoagulants intoxication. Advantages of prothrombin complex concentrates include minimal disruption to haemostasis, rapid administration, fast onset of action and low adverse effect. The aim of this paper is to review current concepts related to prothrombin complex concentrates and their use in the perioperative period.


REFERENCES

  1. Levi J, Tanaka K, Dietrich W. Perioperative hemostatic management of patients treated with vitamin k antagonists. Anesthesiology. 2008;109:918-926.

  2. Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev. 2009;23:177-188.

  3. Leissinger C, Blatt P, Hoots K, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008 83:137-143.

  4. Schick K, Fertmann J, Jauch K, Hoffmann J. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care. 2009;13:1-15.

  5. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42:857-865.

  6. Aiyagari V, Testai F. Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care. 2009;15:87-92.

  7. Painger I, Brenner B, Kalina U, Knaub S, Nagys A. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-631.

  8. Gómez R, Guerra T, Dita L, Damaso J, Cabrera M. Teoría coagulación de las cascadas a las membranas celulares. Med Sur. 2011;9:65-74.

  9. Páramo J, Panizo E, Pegenaute C, Lecumberri R. Coagulación 2009: una visión moderna de la hemostasia. Red Med Uni Navarra. 2009;53:19-23.

  10. Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anesthesiol. 2008;25:784-789.

  11. Liumbruno G, Bernnardello F, Lattanzio A, Piccoli P, Rossetti G; Italian Society of Transfusion Medicine and Immunohemathology (SIMTI) Working Party. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus. 2009;7:325-334.

  12. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology. 2008;109:918-926.

  13. Grobler C, Callum JC, McCluskey SA. Reversal of vitamin K antagonists prior to urgent surgery. Can J Anesth. 2010;57:458-467.

  14. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Gordini G, et al. Management of bleeding following major trauma: a European guideline. Critical Care. 2007;11:17.

  15. Pernod G, Godier A, Gozalo C, Tremey B, Sié P. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res. 2010;126:167-174.

  16. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 1999;45:1113-1118.

  17. Griffee MJ, DeLoughery TG, Thorborg PA. Coagulation management in massive bleeding. Curr Opin Anesthesiol. 2010;23:263-268.

  18. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol. 2007;73:401-415.

  19. Bruce D, Nokes TJC. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12:105.

  20. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, et al. Management of bleeding following major trauma: an updated European guideline. Critical Care. 2010;14:52.

  21. Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen. Critical Care. 2010;14:55.

  22. Cushing M, Shaz BH. Blood transfusion in trauma patients: unresolved questions. Minerva Anestesiol. 2011;77:349-359.

  23. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res. 2001;101:145-157.

  24. Colomina M, Diez A, Garutti I, Gómez A, Llau J, Pita A. Perioperative use of prothrombin complex concentrates. Minerva Anestesiol. 2012;78:358-368.

  25. Fenger C, Munster A, Grove E. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. Acta Anaesthesiol Scand. 2014;58:1-9.

  26. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115:998-1001.

  27. Ageno W, García D, Aguilar MI, Douketis J. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol. 2009;84:584-588.

  28. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation annotation. Br J Haematol. 2001;114:271-280.

  29. Pabinger I, Brenner B, Kalina U, Knaub S. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-631.

  30. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol. 2002;89:400-406.

  31. Frontera J, Gordon E, Zach V, Jovine M, Uchino K, Hussain M, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care. 2014.

  32. Kohler M, Hellstern P, Lechler E, Uberfuhr P. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost. 1998;80:399-402.

  33. Lin D, Murphy L, Tran M. Use of prothrombin complex concentrates and fibrinogen concentrates in the perioperative setting: a systematic review. Transfusion Medicine Reviews. 2013;27:91-104.

  34. Arshad F, Ickx B, Beem R, Polak W, Grüne F, Nevens F, et al. Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. BMC Surgery. 2013;13:22.

  35. Sorensen B, Spahn DR, Innerhofer P, Spannagl M. Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care. 2011;15:201-204.




2020     |     www.medigraphic.com